RUNX2 and prostate cancer: We identified breast cancer enriched TFs including GATA3, PITX2, NR1H2, BCL6, and GSR, CNS-enriched TFs RUNX2, SOX2, and GLIS3, colon cancer-enriched TFs TCF7L2, EHF, HOXA9, and KLF3, leukemia-enriched TFs ZNF692, STAT5B, CELF2, BCL11A, and NFE2, melanoma-enriched TFs including MITF, SNAI2, MAFF, NR4A1, NPAS2, MNT, ETS1, and SCLY, the prostate cancer-enriched TF, FOXA1, and the renal cancer-enriched TF, ATF7 (Fig. 6i).